Biogen Idec Reports Third Quarter 2011 Results MarketWatch (press release) Therapies in Biogen Idec's MS franchise presented at the conference included TYSABRI, BG-12, FAMPYRA(R) (prolonged-release fampridine tablets), AVONEX, and daclizumab high-yield process (DAC HYP). -- On August 9, 2011, Biogen Idec and Abbott announced ... |
